AstraZeneca Purchases US Biologics Manufacturing Facility to Support Growing Pipeline
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Wall St set for higher open as Anthropic's IPO filing sharpens AI focus
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
- Brazilās Lula wins historic fourth term, Flavio Bolsonaro refuses to concede
- Borr Drilling rig sinks off Gabon, one person dead and four missing
- Britain will not join Canada-led defence bank initiativeĀ
- CAE agrees to sell Flightscape unit to SITA for $500 million
- Serbia's Vucic concedes defeat to student led movement in parliamentary election
AstraZeneca (AZN) Acquires Biologics Manufacturing Facility from Amgen (AMGN)
September 11, 2015 7:02 AM EDTAstraZeneca (NYSE: AZN) added to its biologics manufacturing capability in the US with the purchase of a high-tech biologics bulk manufacturing facility from Amgen Inc (Nasdaq: AMGN). Over time, the LakeCentre facility, located in Boulder, Colorado will increase manufacturing and production capacity to support the companys extensive portfolio of biologics medicines.
AstraZeneca plans to start staffing the facility immediately to... More



